Results from the Phase 3 DUO. of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL/SLL
|
|
- Lucinda McDonald
- 6 years ago
- Views:
Transcription
1 Results from the Phase 3 DUO TM Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL/SLL Ian Flinn 1, Peter Hillmen 2, Marco Montillo 3, Zsolt Nagy 4, Árpád Illés 5, Gabriel Etienne 6, Julio Delgado 7,Bryone Jean Kuss 8, Constantine Tam 9, Zoltán Gasztonyi 10, Fritz Offner 11, Scott Lunin 12, Francesco Bosch 13,Matthew Davids 14, Nicole Lamanna 15, Ulrich Jaeger 16, Paolo Ghia 17, Florence Cymbalista 18, Craig Portell 19, Alan Skarbnik 20, Amanda Cashen 21, Virginia Kelly 22, Barry Turnbull 22, Stephan Stilgenbauer 23 1 Sarah Cannon Research Institute, Nashville, USA; 2 St. James's Institute of Oncology, The Leeds Teaching Hospitals, Leeds, UK; 3 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, ITA; 4 1st Department of Internal Medicine, Semmelweis University, Budapest, HUN; 5 Department of Hematology, Institute for Medicine, U. of Debrecen, Debrecen, HUN; 6 Hematology Department, Institut Bergonie, Bordeaux, FRA; 7 Hospital Clinic, Barcelona, SPA; 8 Flinders Medical Centre (FMC), Bedford Park, AUS; 9 Peter MacCallum Cancer Centre, Melbourne, AUS; 10 Dep. of Internal Medicine and Hematology, Petz Aladár County Hospital, Győr, HUN; 11 Hematology, University Hospital Ghent, Gent, BEL; 12 Florida Cancer Specialists, Venice, USA; 13 Department of Hematology, University Hospital Vall d Hebron, Barcelona, SPA; 14 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 15 New York Presbyterian, Columbia University Medical Center, New York, USA; 16 Medical University of Vienna, Vienna, AUT; 17 Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, ITA; 18 Laboratoire d'hématologie, Hôpital Avicenne, Paris, FRA; 19 Division of Hematology and Oncology, University of Virginia, Charlottesville, USA; 20 John Theurer Cancer Center, Hackensack Meridian Health, Closter, USA; 21 Siteman Comprehensive Cancer Center, Washington University, St. Louis, USA; 22 Verastem Inc., Needham, USA; 23 Department III of Internal Medicine, University Hospital Ulm, Ulm, GER
2 Duvelisib is an Oral Dual Inhibitor of PI3K-δ and PI3K-γ Duvelisib targets both malignant B cells (PI3K-δ) and the supportive tumor microenvironment (PI3K-γ) Promising clinical activity (56% ORR per investigator assessment) in a Phase 1 study in advanced CLL/SLL (O Brien ASH 2014) 2
3 DUO: A Phase 3 Randomized Study in Relapsed/Refractory CLL/SLL Optional Crossover Study Relapsed or Refractory CLL/SLL patients 319 patients Randomized 1:1 Duvelisib 25 mg BID continuously * N=160 Ofatumumab IV mg IV infusion on Day mg IV weekly (x7) then monthly (x4) N=159 Ofatumumab IV Administration same as DUO N=8 Duvelisib 25 mg BID continuously N=89 Response per modified iwcll/iwg Criteria ** Assessed by independent review committee (IRC) Cycle 3 (C3), C5, C7, C11, C15, C19, every 6 months thereafter CT scan, CBC, disease related symptoms, BM biopsy *** Survival assessment every 6 months Endpoints PFS (primary) ORR, DOR, OS (secondary) Safety (AEs and lab abnormalities) * Patients may have stopped treatment at C18 for CR/PR >3 months at discretion of Investigator ** Lymphocytosis not considered disease progression; PR = 2 Group A and 1 Group B Criteria *** Required for confirmation of CR/CRi 3
4 Eligibility and Prophylaxis Key Eligibility Criteria - Progressed on or relapsed after 1 prior anticancer therapy - Measurable lymph node disease (> 1.5 cm) per CT scan - Hemoglobin 8.0 g/dl and platelet count 10,000 μl with or without transfusion support - No minimum ANC required - Richter s transformation and prolymphocytic leukemia excluded - Prior treatment with BTK or PI3K inhibitors excluded - Patients with prior, current, or chronic hepatitis B infection excluded Prophylaxis - All patients required to receive Pneumocystis prophylaxis while on treatment - Prophylaxis for CMV infection/reactivation recommended but not required 4
5 Study Enrolled Patients Worldwide US (n=51; 16%) Australia (n=21; 7%) New Zealand (n=12; 4%) Hungary (n=65; 20%) Italy (n=41; 13%) Spain (n=40; 13%) France (n=30; 9%) Belgium (n=27; 9%) UK (n=17; 5%) Austria (n=11; 3%) Germany (n=4; 1%) 5
6 Baseline Characteristics and Prognostic Features Characteristic DUV N = 160 OFA N = 159 CLL/SLL, % 97 / 3 99 / 1 Median age (range), years 69 (39-90) 69 (39-89) Male, % ECOG PS 2, % 7 10 Rai stage 3 / Binet Stage C, % 56 / / 34 Bulky disease ( 5 cm target lesion), % Grade 4 Cytopenia(s), % Molecular features (per central laboratory), % 17p deletion TP53 mutation p deletion and/or TP53 mutation Unmutated IGHV ZAP70 Positive ( 20%)
7 Prior Anticancer Regimens Characteristic DUV N = 160 OFA N = 159 Median prior therapies (range) 2 (1-10) 2 (1-8) Median months from prior therapy (range) 22 (1-149) 18 (1-106) Purine Analog, % Alkylator, % Cyclophosphamide Chlorambucil Bendamustine Monoclonal antibody, % Rituximab Ofatumumab 2 3 Obinutuzumab 1 2 Alemtuzumab 8 3 7
8 Patient Disposition Characteristic DUV OFA Randomized, n Treated, n Median exposure (weeks) Discontinued Treatment, n (%) 124 (79) 155 (100) AE 55 (35) 6 (4) Disease progression 35 (22) 31 (20) Subject withdrawal 13 (8) 7 (5) Death 12 (8) 3 (2) Investigator decision 3 (2) 4 (3) Completed treatment per protocol 1 (1)* 103 (67)* Other 5 (3) 1 (1) On Treatment, n (%) 34 (22) 0 Received opposite treatment on optional crossover study, n (%) 8 (5) 89 (57) *completed treatment for OFA = 7 cycles and for duvelisib = 18 cycles (duvelisib patients permitted to receive duvelisib 18 cycles) 8
9 DUO Met Primary Endpoint of PFS Significantly Longer Median PFS with Duvelisib per IRC DUV OFA Median PFS (Months) % CI 12.1, , 11.3 Hazard ratio 0.52 p-value < Number at Risk 9
10 Significantly Longer PFS with Duvelisib per Investigator Assessment DUV OFA Median PFS (Months) % CI 15, 22 9, 11 Hazard ratio 0.40 p-value < Number at Risk 10
11 Significantly Longer PFS with Duvelisib in Patient with 17p Deletion per IRC DUV OFA Median PFS (Months) % CI 8.9, , 10.8 Hazard ratio 0.41 p-value Number at Risk 11
12 Duvelisib Maintained PFS Advantage in All Subgroups Analyzed 12
13 Percent Significantly Higher ORR with Duvelisib per IRC Overall Response Rate Lymph Node Response Rate % DUV OFA CR 0.6% 0.6% PRwL 0.6% 0 PR 72.5% 44.7% p-value < % Lymph node response: 50% decrease in the SPD of target lymph nodes from baseline % % 10 0 DUV OFA DUV OFA ORR in patients with 17p deletion: duvelisib 70% vs OFA 43% (p=0.0182) 13
14 Overall Survival Similar Between Treatment Arms DUV OFA Median OS (Months) NE NE 95% CI 31, NE 29, NE Hazard ratio 0.99 p-value Number at Risk NE = Not estimable Many patients received a subsequent anticancer therapy 89 patients on OFA arm received duvelisib in crossover study, achieving an ORR of 73% and a median PFS of 15 months per Investigator assessment 14
15 Adverse Events (Percent of Patients) All Grades Grade 3 DUV N=158 OFA N=155 DUV N=158 OFA N=155 Median Observation Period (Weeks) Hematologic Neutropenia Anemia Thrombocytopenia Nonhematologic Diarrhea Pyrexia Nausea Cough Pneumonia Constipation Upper resp. tract infection Vomiting Bronchitis Colitis Decreased appetite Weight decreased Asthenia Abdominal pain Dyspnea Rash
16 AEs of Special Interest Infrequently Led to Duvelisib Discontinuation Rash Pneumonitis Transaminitis Colitis Pneumonia Diarrhea Neutropenia Severe opportunistic infections (6%): bronchopulmonary aspergillosis (n=4), fungal infection (n=2), PJP (n=2)*, and cytomegalovirus colitis (n=1) - No severe Herpes zoster infections All Grade 3 AEs AEs leading to discontinuation (any Grade) Percent of Patients Percent of Patients Treatment-related AEs leading to death (n=4): general health deterioration (n=1); pneumonia staphylococcal (n=2); sepsis (n=1) * Neither patient on prophylaxis at the time of the event 16
17 DUO Study Conclusions DUO met the primary endpoint for PFS: duvelisib monotherapy achieved significant improvement in PFS vs OFA (13.3 m vs 9.9 m; HR = 0.52; p < ) per IRC PFS per investigator response assessment significantly favored duvelisib vs OFA (17.6 m vs 9.7 m; p < ) Similar benefit in CLL/SLL patients with 17p deletion Duvelisib achieved significant improvement in ORR vs OFA (74% vs 45%; p < ) per iwcll/iwg Duvelisib significantly reduced lymph node burden > 50% in most patients vs OFA (85% vs 16%) With a median exposure of 50 weeks, the AE profile of duvelisib was manageable and consistent to what has been previously observed AEs of interest (neutropenia, diarrhea, pneumonia, colitis, transaminase elevations, pneumonitis, rash) infrequently led to discontinuation DUO results support duvelisib oral monotherapy as a potential new and convenient treatment option for previously treated CLL/SLL patients 17
18 THANK YOU We would like to acknowledge the participating institutions, their study investigators and clinical staff, for the successful conduct the study. Most importantly, we sincerely thank our patients and their families for their participation in this clinical study.
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationDYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA Presented at 14-ICML, 14 June 2017, Lugano Switzerland Authors
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationWE STAND UNITED FOR BLOOD CANCER AWARENESS MONTH
WE STAND UNITED FOR BLOOD CANCER AWARENESS MONTH Conference call to discuss FDA approval of COPIKTRA (duvelisib) September 24, 2018 Forward Looking Statements 2 This presentation includes forward-looking
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationACALABRUTINIB IN MCL
ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK BRUTON S TYROSINE KINASE (BTK): A CRITICAL KINASE
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY 3
The Bruton s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study
More informationFrancesc Bosch Department of Hematology University Hospital Vall d Hebron, Barcelona.
Francesc Bosch Department of Hematology University Hospital Vall d Hebron, Barcelona fbosch@vhebron.net www.hematologiavh.net 1. Normal B-cell development and lymphomagenesis 1. Importance of the BCR in
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationInternational Conference on Malignant Lymphoma (ICML) June 14-17, 2017
International Conference on Malignant Lymphoma (ICML) June 14-17, 2017 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR: CLINICAL ACTIVITY AND FAVORABLE SAFETY IN PATIENTS
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Byrd JC, Brown JR, O Brien S, et al. Ibrutinib versus ofatumumab
More informationIdelalisib in CLL New Drugs in Hematology Bologna, 2016
Idelalisib in CLL New Drugs in Hematology Bologna, 2016 S T E V E N C O U T R E P R O F E S S O R O F M E D I C I N E (HEMATOLOGY) S TA N F O R D U N I V E R S I T Y S C H O O L O F M E D I C I N E C O
More informationSecond Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)
Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationMedia Inquiries: Satu Glawe Phone: Bernadette King Phone:
Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationPost-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford
Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype
More informationWhat from the basket of BTK and PI3K inhibitors?
What from the basket of BTK and PI3K inhibitors? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical
More informationHighlights in Chronic Lymphocytic Leukemia From the 60th American Society of Hematology Annual Meeting
January 19 Volume 17, Issue 1, Supplement 1 A SPECIAL MEETING REVIEW EDITION Highlights in Chronic Lymphocytic Leukemia From the 6th American Society of Hematology Annual Meeting A Review of Selected Presentations
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia August 18, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia August 18, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More information2015 Oncology Annual Meeting in Chicago. prime Downloadable Slides in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
2015 Oncology Annual Meeting in Chicago prime Downloadable Slides in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma May 29-June 2 Ibrutinib Combined With Bendamustine and Rituximab in Previously
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationPCI-32765DBL1002. Janssen Research & Development, Raritan, NJ, USA; 9 Janssen Research & Development, Belgrade, Serbia; 10
Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL) Anas Younes, 1 Ian
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationIdelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationTisch Cancer Institute, Icahn School of Medicine at Mount Sinai; MPN-RC (US), 2 H Lee Moffitt Cancer Center (US), 3
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1
RETHINK WHAT S POSSIBLE... ZYDELIG (idelalisib) PBS LISTED 1 st 1 September 2017 ZYDELIG a first-in-class oral PI3Kδ inhibitor is PBS listed from 1 st September 2017 for the treatment of: Double-refractory
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationEfficacy of Bendamustine and rituximab in a real-world patient population
Efficacy of Bendamustine and rituximab in a real-world patient population Median follow-up 37,1 months Efficacy of bendamustine and rituximab as first salvage treatment in CLL and indirect comparison with
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationPage 1. DOSAGE AND ADMINISTRATION 25 mg orally, twice daily. Modify dosage for toxicity. (2.1, 2.2) HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA. COPIKTRA (duvelisib),
More informationDebate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationFollicular Lymphoma New Agents. Idelalisib
Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationpreviously treated genetically high-risk of the GENUINE phase 3 study
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the GENUINE phase 3 study Jeff P. Sharman, 1, 17 Danielle M. Brander, 2 Anthony Mato, 3 Suman
More informationDefining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia
Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More information